/
We are a leading national provider of diagnostic imaging services in the United States based on number of locations and annual imaging revenue. As of December 31, 2025, we operated, directly or indirectly through hospital and health system joint ventures, 418 imaging centers located in Arizona, California, Delaware, Florida, Maryland, Virginia, New Jersey, Texas and New York.
$62.19
$0.80 (-1.27%)
EOD Jul 17, 2026
Operating margin is thin at 3.04%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 11.5%, still solid. Margins contracted 2.7pp, which offsets some of the top-line progress.
ROIC dropped from 4.11% to 1.67%, capital efficiency is deteriorating. Net debt of $1.12B represents 13.1x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.14B
▲ +11.5% YoY
Net Income (TTM)
-$14M
▼ -767.8% YoY
Op. Margin
2.90%
▼ -2.7pp YoY
ROIC
1.77%
▼ -2.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$102M
▲ +90.4% YoY
Op. Cash Flow (TTM)
$336M
▲ +28.2% YoY
Net Debt
$1.51B
Cash & Equiv.
$455M
5Y CAGR: +13.7%
5Y CAGR: -9.3%
Continue Research
RadNet (RDNT) trades above a two-stage DCF intrinsic value of about $47.25 per share, so at $62.19 the stock looks overvalued (24.0% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, RadNet scores 39/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $47.25 per share for RDNT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $35.44. At today's $62.19, that puts the stock about 24.0% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
RadNet scores 39 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.9% operating margin and a 1.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. RDNT currently trades above its estimated intrinsic value and scores 39/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.